Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SD-1240** is a VHL-based PROTAC (proteolysis targeting chimera) degrader specifically designed to target **STAT3** (Signal Transducer and Activator of Transcription 3), a transcription factor implicated in oncogenesis. It induces potent and selective depletion of STAT3 protein, leading to suppression of tumor growth in preclinical models. SD-1240 demonstrates strong anti-proliferative effects in a subset of **acute myeloid leukemia (AML)** and **anaplastic large cell lymphoma (ALCL)** cell lines, highlighting its potential as a targeted therapy for STAT3-driven hematologic malignancies.[1][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SD-1240.